CEDAR KNOLLS, N.J.,
July 31, 2019 /PRNewswire/
-- MYOS RENS Technology Inc. ("MYOS" or "the Company")
(NASDAQ: MYOS), an advanced nutrition company and the owner of
Fortetropin®, a proprietary bioactive composition
derived from fertilized egg yolk that helps build lean muscle, will
announce financial results for the second quarter and first half of
2019 on Tuesday, August 6 after the
market closes.
The Company will host a conference call on Wednesday, August 7, 2019 at 11:00 am ET, at which time MYOS Chief Executive
Officer Joseph Mannello will provide
commentary on earnings results and provide updates on its ongoing
clinical studies and commercial efforts.
Conference Call Details:
Call Date/Time: Wednesday, August 7, 2019 at
11:00 am ET
Dial In: 877-407-4019 from the U.S.; international
callers may telephone 201-689-8337, approximately 15 minutes before
the call.
A digital replay will be available by telephone
approximately two hours after the completion of the call until
November 9, 2019 and may be accessed
by dialing 877-660-6853 from the U.S. or 201-612-7415 for
international callers, using the Conference ID# 13693294.
This call will be simultaneously webcast. The webcast will be
available on the MYOS website, www.myosrens.com, in the "Investor
Relations" section. The webcast will be archived and available at
the same web address for two weeks following the call.
About MYOS RENS Technology Inc.
MYOS RENS
Technology Inc. (MYOS), "The Muscle Company®", is a
Cedar Knolls, NJ-based advanced
nutrition company that develops and markets products that improve
muscle health and performance. MYOS is the owner of
Fortetropin®, a fertilized egg yolk-based product
manufactured via a proprietary process to retain and optimize its
biological activity. Fortetropin has been clinically shown to
increase muscle size and lean body mass in conjunction with
resistance training. MYOS believes Fortetropin has the potential to
redefine existing standards of physical health and wellness. For
more information, please visit www.MYOSRENS.com.
Forward-Looking Statements
Any statements
in this release that are not historical facts are forward-looking
statements. Actual results may differ materially from those
projected or implied in any forward-looking statements. Such
statements involve risks and uncertainties, including but not
limited to those relating to product and customer demand, market
acceptance of our products, the ability to create new products
through research and development, the successful results of
strategic initiatives, the success of our products, including
Qurr®, Yolked®, MYOS Enteral
Nutrition Formula™ and MYOS Canine Muscle
Formula® , the success of our research and
development, the results of the clinical evaluation
of Fortetropin® and its effects, the
ability to enter into new partnership opportunities and the success
of our existing partnerships, the ability to generate revenue and
cash flow from sales of our products, the ability to increase our
revenue and gross profit margins, the ability to achieve a
sustainable, profitable business, the effect of economic
conditions, the ability to protect our intellectual property
rights, competition from other providers and products, the
continued listing of our securities on the Nasdaq Stock Market,
risks in product development, our ability to raise capital to fund
continuing operations, and other factors discussed from time to
time in our filings with the Securities and Exchange
Commission. We undertake no obligation to update or revise any
forward-looking statement for events or circumstances after the
date on which such statement is made except as required by
law.
These statements have not been evaluated by the Food and Drug
Administration. Our products are not intended to diagnose, treat,
cure or prevent any disease.
Investor Relations:
Porter LeVay & Rose
Matthew Abenante, IRC, SVP
Phone: 212-564-4700
Email: MYOS@plrinvest.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/myos-rens-technology-announces-the-date-for-the-release-of-second-quarter-and-first-half-2019-results-conference-call-and-webcast-300894203.html
SOURCE MYOS RENS Technology